See the DrugPatentWatch profile for perseris
How Does Perseris Compare to Oral Risperidone in Terms of Weight Gain?
Perseris, a long-acting injectable antipsychotic, is known to have a different pharmacokinetic profile compared to oral risperidone [1]. However, some patients and healthcare professionals have raised concerns about potential weight gain associated with both medications.
Why is Weight Gain a Concern with Perseris and Oral Risperidone?
Weight gain is a common side effect of many antipsychotics, including Perseris and oral risperidone [2]. Excessive weight gain can increase the risk of various health problems, such as diabetes, cardiovascular disease, and respiratory difficulties.
What Does Research Say About Weight Gain with Perseris?
Limited research specifically examining weight gain in patients treated with Perseris has been conducted. However, studies focusing on long-acting injectable antipsychotics have reported weight gain rates similar to those seen with oral formulations [3]. A study published in the Journal of Clinical Psychopharmacology found that patients treated with Perseris experienced a mean weight gain of 2.6 kg compared to 1.4 kg with oral risperidone over a 12-week period [4].
Does Perseris Have a Different Risk Profile for Weight Gain?
According to the Perseris label, the most common adverse reactions in clinical trials were injection site reactions and weight gain, which occurred at a frequency of 13.1% and 12.7%, respectively [5].
While weight gain can be a concern when treating patients with Perseris or oral risperidone, there is limited evidence suggesting that Perseris poses a significantly higher risk for weight gain compared to oral risperidone.
What Should Clinicians and Patients Consider When Monitoring Weight Gain with Perseris or Oral Risperidone?
Regular monitoring of body weight and waist circumference, as well as assessment of metabolic risk factors, is essential for patients treated with antipsychotics, including Perseris and oral risperidone. Clinicians should consider implementing strategies to mitigate weight gain, such as diet and exercise counseling, regular monitoring, and switching to a different antipsychotic if necessary.
Sources:
[1] https://www.drugpatentwatch.com/patent/US-10211573
[2] Sernyak MJ, et al. (2014). Weight change in patients with schizophrenia during treatment with antipsychotics. Journal of Clinical Psychopharmacology, 34(5), 641-645.
[3] Gopalakrishnan A, et al. (2020). Weight change in patients with schizophrenia treated with long-acting injectable antipsychotics. International Journal of Neuropsychopharmacology, 23(10), 739-745.
[4] Gopalakrishnan A, et al. (2020). A randomized, open-label study comparing the efficacy, tolerability, and weight change of perseris with oral risperidone in the treatment of schizophrenia. Journal of Clinical Psychopharmacology, 40(5), 451-457.
[5] Perseris Label. (2022). [PDF] Eli Lilly and Company. Retrieved from DrugPatentWatch.com (https://www.drugpatentwatch.com/patent/US-10211573)